Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
metaflumizone
Pfizer Limited
QP53AX25
metaflumizone
Cats
Ectoparasiticides for topical use, incl. insecticides
Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Revision: 8
Withdrawn
2006-12-19
Medicinal product no longer authorised B. PACKAGE LEAFLET 19 Medicinal product no longer authorised PACKAGE LEAFLET PROMERIS SPOT-ON FOR CATS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom Manufacturer for the batch release Wyeth Lederle Italia S.p.A. 18, Via Franco Gorgone 95121 Catania Italy 2. NAME OF THE VETERINARY MEDICINAL PRODUCT ProMeris 160 mg Spot-on for small cats ProMeris 320 mg Spot-on for large cats 3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS ACTIVE SUBSTANCE Each ml contains 200 mg metaflumizone Each unit dose (pipette) of ProMeris delivers: Volume (ml) Metaflumizone (mg) ProMeris for Small Cats (≤ 4 kg)* 0.80 160 ProMeris for Large Cats (> 4 kg)* 1.60 320 *DUE TO LIMITED SPACE ON THE PACKAGING, THE ABBREVIATIONS "S" AND "L", WHICH REPRESENT "SMALL" AND "LARGE", RESPECTIVELY, ARE USED ON THE BLISTER FOIL AND APPLICATOR PIPETTES. 4. INDICATION(S) Treatment and prevention of flea infestations ( _Ctenocephalides canis _ and _ C._ _felis_ ) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD). 5. CONTRAINDICATIONS Do not use in kittens under 8 weeks of age. In sick or debilitated animals use only according to the benefit/risk assessment. 20 Medicinal product no longer authorised 6. ADVERSE REACTIONS* Hypersalivation may occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within minutes without treatment. Correct application will minimise licking of the application site. The application of the veterinary medicinal product may produce a local, temporary oily appearance and clumping or spiking of the fur at the application site. A dry residue may also be observed. This is normal and will generally resolve within 1 – 4 days after administration. These ch Lestu allt skjalið
Medicinal product no longer authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 Medicinal product no longer authorised 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ProMeris 160 mg Spot-on solution for small cats ProMeris 320 mg Spot-on solution for large cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCES Each ml contains 200 mg metaflumizone. Each unit dose (pipette) of ProMeris delivers: VOLUME (ML) METAFLUMIZONE (MG) ProMeris for Small Cats (≤ 4 kg) 0.80 ml 160 mg ProMeris for Large Cats (> 4 kg) 1.60 ml 320 mg EXCIPIENTS For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Spot-on solution A clear, yellow to amber solution 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats over 8 weeks of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment and prevention of flea infestations ( _Ctenocephalides_ _canis and C._ _felis_ ) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD). 4.3 CONTRAINDICATIONS Do not administer to kittens under 8 weeks of age. 4.4 SPECIAL WARNINGS Avoid contact with the eyes of the cat and avoid oral ingestion by the animal. For optimum control of flea problems in a multi-pet household, all pets in the household should be treated with a suitable insecticide. In addition it is recommended to treat the environment with a suitable insecticide. 2 Medicinal product no longer authorised 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS In sick or debilitated animals, use only according to the benefit/risk assessment by the responsible veterinarian. This veterinary medicinal product is for spot-on application only. Do not administer orally or via any other route. It is important to apply the dose to an area where the animal cannot lick it off. Do not allow animals to groom each other following treatment. Care should be taken to ensure that the content of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/or ot Lestu allt skjalið